Several FDA-approved small-molecule inhibitors such as idelalisib [55], copanlisib [56], and duvelisib [57] targeting the PI3K/Akt/mTOR pathway are currently in clinical development at various stages for the treatment of lymphoma. This evidence concerns the gene AKT1 and lymphoma.